Federal Register / Vol. 60, No. 2 / Wednesday, January 4, 1995 / Notices 469

1Copies of the Complaint and the Decision and

Order are available from the Commission’s Public

Reference Branch, H–130, 6th Street & Pennsylvania

Avenue, N.W., Washington, D.C. 20580.

Communicator enable autistic

individuals to communicate through

facilitated communication. The

complaint also alleges that respondent

lacked substantiation for these claims.

The proposed consent order contains

provisions designed to remedy the

violations charged and to prevent the

respondent from engaging in similar

acts and practices in the future.

Part I of the proposed order prohibits

respondent from misrepresenting that

any communication aid enable autistic

individuals to communicate through

facilitated communication.

As fencing-in relief, Part II of the

proposed order provides that, if the

respondent represents that a

communication aid enables individuals

with disabilities to communicate

through facilitated communication, the

representation must be true and

respondent must possess competent and

reliable scientific evidence that

substantiates the representation. In

addition, Part II of the proposed order

prohibits respondent from representing

the performance or attributes of a

communication aid unless it possesses

and relies upon competent and reliable

evidence, which when appropriate must

be competent and reliable scientific

evidence, to substantiate the

representation.

The proposed order also requires

respondent to maintain materials relied

upon to substantiate claims covered by

the order; to provide a copy of the

consent agreement to its employees

involved in the preparation and

placement of respondent’s

advertisements, or in communication

with respondent’s customers or

prospective customers; to notify the

Commission of any change in the

corporate structure that might affect

compliance with the order; and to file

one or more reports detailing

compliance with the order.

The purpose of this analysis is to

facilitate public comment on the

proposed order. It is not intended to

constitute an official interpretation of

the agreement and proposed order or to

modify in any way their terms.

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 95–94 Filed 1–3–95: 8:45 am]

BILLING CODE 6750–01–M

[Dkt. C–3546]

Rite Aid Corporation; Prohibited Trade

Practices, and Affirmative Correction

Actions

AGENCY: Federal Trade Commission.

ACTION: Consent order.

SUMMARY: In settlement of alleged

violations of federal law prohibiting

unfair acts and practices and unfair

methods of competition, this consent

order requires, among other things, Rite

Aid, in conjunction with its acquisition

of LaVerdiere’s Enterprises, Inc., to

divest the pharmacy assets either in its

own Rite Aid stores, or in the

LaVerdiere’s stores it will acquire, in

three specified cities, to a Commissionapproved entity within 12 months of the

order. If the divestitures are not

accomplished within the time-frame,

the Commission can appoint a trustee to

accomplish them. In addition, the

consent order requires the respondent,

for a period of ten years, to obtain

Commission approval before acquiring

any assets or stocks in any entity

engaged in the business of selling

prescription drugs at retail outlets in the

three designated cities.

DATES: Complaint and Order issued

December 15, 1994.1

FOR FURTHER INFORMATION CONTACT: Ann

Malester or Catharine Moscatelli, FTC/

S–2224, Washington, D.C. 20580. (202)

326–2682 or 326–2749.

SUPPLEMENTARY INFORMATION: On

Monday, September 12, 1994, there was

published in the Federal Register, 59 FR

46843, a proposed consent agreement

with analysis In the Matter of Rite Aid

Corporation, for the purpose of

soliciting public comment. Interested

parties were given sixty (60) days in

which to submit comments, suggestions

or objections regarding the proposed

form of the order.

Comments were filed and considered

by the Commission. The Commission

has ordered the issuance of the

complaint in the form contemplated by

the agreement, made its jurisdictional

findings and entered an order to divest,

as set forth in the proposed consent

agreement, in disposition of this

proceeding.

(Sec. 6, 38 Stat. 721; 15 U.S.C. 46. Interpret

or apply sec. 5, 38 Stat. 719, as amended; sec.

7, 38 Stat. 731, as amended; 15 U.S.C. 45, 18)

Benjamin I. Berman,

Acting Secretary.

[FR Doc. 95–95 Filed 1–3–95; 8:45 am]

BILLING CODE 6750–01–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Invention;

Availability for Licensing

AGENCY: National Institutes of Health,

HHS.

ACTION: Notice.

SUMMARY: The invention listed below is

owned by an agency of the U.S.

Government and is available for

licensing in the U.S. (and in foreign

markets) in accordance with 35 U.S.C.

207 to achieve expeditious

commercialization of results of federally

funded research and development.

A ‘‘Method And System For

Measuring The Diffusion Tensor And

For Diffusion Tensor Imaging’’ was

developed by P.J. Basser and J.H.

Mattiello of the National Center for

Research Resources and D. LeBinah of

the Warren Grant Magnuson Clinical

Center. The National Institutes of Health

is the assignee of patent rights to this

technology, which are covered under

U.S. Patent Application Number 08/

103,009, filed August 6, 1993.

This application describes a new

modality of nuclear magnetic resonance

imaging. Specifically, this is a method

and system for measuring the diffusion

tensor and for generating images related

to the diffusion tensor. Several

advantages can be achieved with this

method and system for measuring the

effective diffusion tensor for spinlabeled nuclei. The diffusion tensor may

be used for generating a diffusion

ellipsoid for the measured region. Such

techniques may be used for imaging

fiber orientation in tissue.

Measurements in diffusion tensor may

also be used for aligning and calibrating

the magnetic field gradients of the NMR

apparatus itself.

ADDRESSES: Licensing information and

copies of the U.S. patent application

may be obtained by writing to J.E.

Fahner-Vihtelic at the Office of

Technology Transfer, National Institutes

of Health, 6011 Executive Boulevard,

Suite 325, Rockville, Maryland 20852–

3804 (telephone 301/496–7735 ext. 285;

fax 301/402–0220). A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent application.

Dated: December 20, 1994.

Barbara M. McGarey,

Deputy Director, Office of Technology

Transfer.

[FR Doc. 95–46 Filed 1–3–95; 8:45 am]

BILLING CODE 4140–01–P